About
Deverra Therapeutics develops allogeneic, off-the-shelf universal donor cellular immunotherapies derived from umbilical cord blood cells for treating cancer and infectious diseases, advancing multiple clinical-stage programs including stem/progenitor cell and immune effector cell therapies.
Explore Deverra Therapeutics, Inc.'s full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.